Acasă › Mielom multiplu › North Carolina › Durham
Studii clinice pentru Mielom multiplu în Durham, NC
37 studii pentru Mielom multiplu caută participanți în și în jurul orașului Durham (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
În curs de recrutareFaza 3
- Research Site, Chapel Hill · La 10 mi distanță
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
În curs de recrutareFaza 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · La 10 mi distanță
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
În curs de recrutareFaza 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
În curs de recrutareFaza 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · La 10 mi distanță
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
În curs de recrutareFaza 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · La 10 mi distanță
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
În curs de recrutareFaza 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 2
- University of North Carolina Medical Center, Chapel Hill · La 10 mi distanță
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
În curs de recrutareFaza 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · La 10 mi distanță
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
În curs de recrutareFaza 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · La 13 mi distanță
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
În curs de recrutareFaza 1/2
- GSK Investigational Site, Chapel Hill · La 10 mi distanță
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
În curs de recrutareFaza 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
În curs de recrutareFaza 3
- Research Site, Durham
- Research Site, Chapel Hill · La 10 mi distanță
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
În curs de recrutare
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · La 10 mi distanță
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
În curs de recrutareFaza 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · La 10 mi distanță
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
În curs de recrutareFaza 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · La 10 mi distanță
Selinexor and Backbone Treatments of Multiple Myeloma Patients
În curs de recrutareFaza 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- University of North Carolina /ID# 251203, Chapel Hill · La 10 mi distanță
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
În curs de recrutareFaza 1
- University of North Carolina at Chapel Hill, Chapel Hill · La 10 mi distanță
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
În curs de recrutareFaza 2
- University of North Carolina (Data Collection Only), Chapel Hill · La 10 mi distanță
Registry of Older Patients With Cancer
În curs de recrutareStudiu observațional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · La 10 mi distanță
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
În curs de recrutareFaza 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
În curs de recrutareFaza 2
- University of North Carolina, Chapel Hill · La 10 mi distanță
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
În curs de recrutareFaza 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · La 10 mi distanță
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · La 10 mi distanță
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
În curs de recrutareFaza 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · La 13 mi distanță
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
În curs de recrutareFaza 1
- University of North Carolina, Chapel Hill · La 10 mi distanță
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
În curs de recrutareFaza 1
- University of North Carolina, Chapel Hill · La 10 mi distanță
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
În curs de recrutareFaza 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · La 10 mi distanță
Registry for Adults With Plasma Cell Disorders (PCD's)
În curs de recrutareStudiu observațional
- North Carolina Cancer Hospital, Chapel Hill · La 10 mi distanță
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
În curs de recrutareStudiu observațional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · La 10 mi distanță
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Duke University Health System (DUHS), Durham
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Boston, MA42 studii
- Atlanta, GA41 studii
- Houston, TX38 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- St. Louis, MO24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Chicago, IL22 studii
- Seattle, WA22 studii
Alte studii în Durham
- Cancer de sân63 studii
- Cancer (toate tipurile)58 studii
- Cancer pulmonar cu celule non-pătrate39 studii
- Cancer metastatic33 studii
- Leucemie mieloasă acută33 studii
- Cancer pulmonar32 studii
- Cancer de prostată32 studii
- Cancer colorectal28 studii
- Leucemie limfatică cronică27 studii
- Cancer ovarian27 studii
- Insuficiență cardiacă26 studii
- Cancer pancreatic24 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.